erlotinib has been researched along with colchicine in 7 studies
| Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (colchicine) | Trials (colchicine) | Recent Studies (post-2010) (colchicine) |
|---|---|---|---|---|---|
| 221 | 0 | 180 | 15,472 | 404 | 2,974 |
| Protein | Taxonomy | erlotinib (IC50) | colchicine (IC50) |
|---|---|---|---|
| Tubulin alpha-1A chain | Sus scrofa (pig) | 3.7639 | |
| Tubulin beta chain | Sus scrofa (pig) | 3.8663 | |
| Tubulin beta-4A chain | Homo sapiens (human) | 2.4334 | |
| Tubulin beta chain | Homo sapiens (human) | 2.7244 | |
| Tubulin alpha-3C chain | Homo sapiens (human) | 2.4334 | |
| Serine/threonine-protein kinase pim-1 | Homo sapiens (human) | 4.3 | |
| Tubulin alpha-1B chain | Homo sapiens (human) | 2.4334 | |
| Tubulin alpha-4A chain | Homo sapiens (human) | 2.4334 | |
| Tubulin beta-4B chain | Homo sapiens (human) | 2.4334 | |
| Vesicular acetylcholine transporter | Tetronarce californica (Pacific electric ray) | 2.62 | |
| Tubulin beta-3 chain | Homo sapiens (human) | 2.4334 | |
| Tubulin beta-2A chain | Homo sapiens (human) | 2.4334 | |
| Tubulin beta-8 chain | Homo sapiens (human) | 2.4334 | |
| Tubulin beta-2B chain | Bos taurus (cattle) | 2.8255 | |
| Tubulin alpha-3E chain | Homo sapiens (human) | 2.4334 | |
| Tubulin alpha-1A chain | Homo sapiens (human) | 2.4334 | |
| Similar to alpha-tubulin isoform 1 | Bos taurus (cattle) | 3.0611 | |
| Similar to alpha-tubulin isoform 1 | Bos taurus (cattle) | 3.1553 | |
| Tubulin alpha-1C chain | Homo sapiens (human) | 2.4334 | |
| Tubulin beta-6 chain | Homo sapiens (human) | 2.4334 | |
| Tubulin beta-2B chain | Homo sapiens (human) | 2.4334 | |
| Tubulin beta-1 chain | Homo sapiens (human) | 2.4334 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| El-Ashmawy, MB; El-Gohary, NS; Shehata, IA; Warda, ET | 1 |
| Abuo-Rahma, GEA; Badr, M; Bass, AKA; El-Zoghbi, MS; Mohamed, MFA; Nageeb, EM | 1 |
| Arya, GC; Jaitak, V; Kaur, K | 1 |
3 review(s) available for erlotinib and colchicine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Benzimidazoles; Cyclic Nucleotide Phosphodiesterases, Type 5; Daunorubicin; Doxorubicin; fms-Like Tyrosine Kinase 3; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Targeted Therapy; Morpholines; Nicotinamide Phosphoribosyltransferase; Nitric Oxide; Pyrimidines; Quinazolines; Structure-Activity Relationship; Transcription Factors | 2021 |
Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Drug Screening Assays, Antitumor; Female; Humans; Isoxazoles | 2021 |
4 other study(ies) available for erlotinib and colchicine
| Article | Year |
|---|---|
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
New series of isoxazole derivatives targeting EGFR-TK: Synthesis, molecular modeling and antitumor evaluation.
Topics: Apoptosis; Binding Sites; Caspase 3; Cell Line, Tumor; Cell Survival; DNA Topoisomerases, Type II; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; G2 Phase Cell Cycle Checkpoints; Humans; Isoxazoles; Molecular Docking Simulation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Structure-Activity Relationship; Up-Regulation; Vascular Endothelial Growth Factor Receptor-2 | 2020 |